Ocugen News

Trending Stocks Today: NANO Nuclear Energy Inches up 8.83% Post-Market

Moomoo NewsJun 28 16:30 ET

Sector Update: Health Care Stocks Steady Premarket Friday

MT NewswiresJun 21 09:12 ET

Ocugen's Receives Nod to Enrol in High Dose Study of Stargardt Disease Drug Candidate

MT NewswiresJun 21 08:04 ET

Express News | Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in Gardian Study for Stargardt Disease

ReutersJun 21 07:00 ET

Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

OcugenJun 21 00:00 ET

Express News | Ocugen Shares Are Trading Lower. The Company Announced That the First Patient Has Been Dosed in Its Phase 3 LiMeliGhT Clinical Trial for OCU400—a Modifier Gene Therapy Product Candidate Being Developed for Retinitis Pigmentosa

BenzingaJun 20 11:25 ET

Ocugen Begins Phase 3 Trial for Gene Therapy to Treat Retinitis Pigmentosa

BenzingaJun 20 06:32 ET

Express News | Ocugen Inc - Ocu400 Remains on Track for 2026 Bla and Maa Approval Targets

ReutersJun 20 06:30 ET

Express News | Ocugen, Inc. Announces First Patient Dosed in Phase 3 Limelight Clinical Trial for Ocu400—First Gene Therapy in Phase 3 With a Broad Retinitis Pigmentosa Indication

ReutersJun 20 06:30 ET

Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

BenzingaJun 20 05:29 ET

Ocugen, Inc. Announces First Patient Dosed in Phase 3 LiMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 With a Broad Retinitis Pigmentosa Indication

OcugenJun 20 00:00 ET

Mississippi Retina Associates: Revolutionizing Retinal Care

BusinesswireJun 5 15:38 ET

Ocugen (OCGN) Skyrockets 209.6% Year to Date: Heres Why

Yahoo FinanceJun 5 09:25 ET

Sector Update: Health Care Stocks Advance Friday Afternoon

MT NewswiresMay 31 14:02 ET

(OCGN) - Analyzing Ocugen's Short Interest

BenzingaMay 31 11:30 ET

Ocugen Gets Recommendation For Dose Escalation in Eye Disease Trial; Shares Climb

MT NewswiresMay 31 11:16 ET

Express News | Ocugen Announces Data And Safety Monitoring Board Has Recommended To Proceed With Dosing Subsequent GA Subjects With Low Dose Of OCU410 In Dose-Expansion Phase And Concurrently Initiate Phase 2 Dosing

BenzingaMay 31 08:39 ET

Express News | Ocugen Inc -Dsmb Recommends Continuing With High-Dose Cohort Dosing With Concurrent Phase 2 Dosing

ReutersMay 31 08:37 ET

Express News | Ocugen Inc -Established Medium Dose as Safe and Tolerable Dose in Current Ocu410 Clinical Trial

ReutersMay 31 08:37 ET

Express News | Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in Ocu410 Armada Study for Geographic Atrophy

ReutersMay 31 08:37 ET